Evaluation of models for predicting pediatric fraction unbound in plasma for human health risk assessment

References

• Barre, J., G. Houin, J. Rosenbaum, R. Zini, D. Dhumeaux, and J. P. Tillement. 1984. Decreased alpha 1-acid glycoprotein in liver cirrhosis: Consequences for drug protein binding. Br. J. Clin. Pharmacol. 18:652–53. doi:10.1111/j.1365-2125.1984.tb02525.x.
   PubMed Web of Science ®Google Scholar
• Besunder, J. B., M. D. Reed, and J. L. Blumer. 1988. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin Pharmacokinet 14:189–216. doi:10.2165/00003088-198814040-00001.
   PubMed Web of Science ®Google Scholar
• Bhat, V. S., M. Meek, M. Valcke, C. English, A. Boobis, and R. Brown. 2017. Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; Increasing utility and facilitating regulatory acceptance. Crit. Rev. Toxicol. 47:733–53.
   Web of Science ®Google Scholar
• Brodersen, R., C. Jacobsen, H. Iversen, and F. Lundquist. 1984. The chemical nature of fetal albumin. In Neonatal jaundice, ed. Rubaltelli F. F., Jori G., pp.  51–54. Springer, Boston, MA.
   Google Scholar
• Burton, M. E., J. Schentag, L. M. Shaw, and W. E. Evans. 2006. Applied pharmacokinetics & pharmacodynamics: Principles of therapeutic drug monitoring. 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
   Google Scholar
• Cartlidge, P. H., and N. Rutter. 1986. Serum albumin concentrations and oedema in the newborn. Arch. Dis. Child. 61:657–60. doi:10.1136/adc.61.7.657.
   PubMedGoogle Scholar
• Clewell, H. J., P. R. Gentry, T. R. Covington, R. Sarangapani, and J. G. Teeguarden. 2004. Evaluation of the potential impact of age-and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79:381–93.
   PubMed Web of Science ®Google Scholar
• Edginton, A. N., W. Schmitt, B. Voith, and S. Willmann. 2006a. A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet 45:683–704.
   PubMed Web of Science ®Google Scholar
• Edginton, A. N., W. Schmitt, and S. Willmann. 2006b. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet 45:1013–34.
   PubMed Web of Science ®Google Scholar
• Ehrnebo, M., S. Agurell, B. Jalling, and L. O. Boreus. 1971. Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. Eur. J. Clin. Pharmacol. 3:189–93.
   PubMed Web of Science ®Google Scholar
• Fredholm, B. B., A. Rane, and B. Persson. 1975. Diphenylhydantoin binding to proteins in plasma and its dependence on free fatty-acid and bilirubin concentration in dogs and newborn-infants. Pediatr. Res. 9:26–30. doi:10.1203/00006450–197509010–00005.
   Web of Science ®Google Scholar
• Fujita, H., T. Okada, I. Inami, M. Makimoto, S. Hosono, M. Minato, S. Takahashi, H. Mugishima, and T. Yamamoto. 2008. Low-density lipoprotein profile changes during the neonatal period. J. Perinatol. 28:335–40. doi:10.1038/jp.2008.8.
   PubMed Web of Science ®Google Scholar
• Holt, D. W., A. M. Hayler, and G. F. Healey. 1983. Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide. Br. J. Clin. Pharmacol. 16:344–45. doi:10.1111/j.1365-2125.1983.tb02175.x.
   PubMed Web of Science ®Google Scholar
• Hozo, S. P., B. Djulbegovic, and I. Hozo. 2005. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol 5:13. doi:10.1186/1471-2288-5-13.
   PubMedGoogle Scholar
• Huwaldt, J. A., and S. Steinhorst. 2013. Plot digitizer http://plotdigitizer.Sourceforge.Net
   Google Scholar
• Ingle, B. L., B. C. Veber, J. W. Nichols, and R. Tornero-Velez. 2016. Informing the human plasma protein binding of environmental chemicals by machine learning in the pharmaceutical space: Applicability domain and limits of predictability. J. Chem. Inf. Model 56:2243–52. doi:10.1021/acs.jcim.6b00291.
   PubMed Web of Science ®Google Scholar
• International Programme on Chemical Safety. 2001. Guidance document for the use of data in development of chemical-specific adjustment factors (CSAFs) for-interspecies differences and human variability in dose/concentration–response assessment. Switzerland: World Health Organization Geneva.
   Google Scholar
• Israili, Z. H., and P. G. Dayton. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33:161–235. doi:10.1081/DMR-100104402.
   PubMed Web of Science ®Google Scholar
• Johnson, T. N., A. Rostami-Hodjegan, and G. T. Tucker. 2006. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931–56. doi:10.2165/00003088-200645090-00005.
   PubMed Web of Science ®Google Scholar
• Kanakoudi, F., V. Drossou, V. Tzimouli, E. Diamanti, T. Konstantinidis, A. Germenis, and G. Kremenopoulos. 1995. Serum concentrations of 10 acute-phase proteins in healthy term and preterm infants from birth to age 6 months. Clin. Chem. 41:605–08.
   PubMed Web of Science ®Google Scholar
• Kearns, G. L., S. M. Abdel-Rahman, S. W. Alander, D. L. Blowey, J. S. Leeder, and R. E. Kauffman. 2003. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N. Eng. J. Med. 349:1157–67.
   PubMed Web of Science ®Google Scholar
• Kim, S., J. Chen, T. J. Cheng, A. Gindulyte, J. He, S. Q. He, Q. L. Li, B. A. Shoemaker, P. A. Thiessen, B. Yu, et al. 2019. Pubchem 2019 update: Improved access to chemical data. Nucleic Acids Res. 47:D1102–D1109. doi:10.1093/nar/gky1033.
   PubMed Web of Science ®Google Scholar
• Kim, Y. S., I. S. Sol, M. J. Kim, S. Y. Kim, J. D. Kim, Y. H. Kim, K. W. Kim, M. H. Sohn, and K. E. Kim. 2017. Serum albumin as a biomarker of poor prognosis in the pediatric patients in intensive care unit. Acute Crit. Care 32:347–55. doi:10.4266/kjccm.2017.00437.
   Web of Science ®Google Scholar
• Koehntop, D. E., J. H. Rodman, D. M. Brundage, M. G. Hegland, and J. J. Buckley. 1986. Pharmacokinetics of fentanyl in neonates. Anesth. Analg. 65:227–32.
   PubMed Web of Science ®Google Scholar
• Lambrinidis, G., T. Vallianatou, and A. Tsantili-Kakoulidou. 2015. In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review. Adv. Drug Deliv. Rev. 86:27–45. doi:10.1016/j.addr.2015.03.011.
   PubMed Web of Science ®Google Scholar
• Lehman-McKeeman, L. D. 2010. Chapter 5. Absorption, distribution, and excretion of toxicants. In Casarett & Doull’s essentials of toxicology, 2 ed, pp. 57–70 McGraw Hill Professional, New York, NY.
   Google Scholar
• Lemaire, M., S. Urien, E. Albengres, P. Riant, and R. Zini. 1986. Lipoprotein binding of drugs. In Drug–protein binding, ed. M. M. Reidenberg and S. Erill, pp. 93–108. Praeger Publishers, Westport, NY, USA.
   Google Scholar
• Maharaj, A. R., and A. N. Edginton. 2014. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. Pharmacometrics Syst. Pharmacol. 3:1–13. doi:10.1038/psp.2014.45.
   PubMedGoogle Scholar
• Maharaj, A. R., D. Gonzalez, M. Cohen-Wolkowiez, C. P. Hornik, and A. N. Edginton. 2018. Improving pediatric protein binding estimates: An evaluation of alpha1-acid glycoprotein maturation in healthy and infected subjects. Clin Pharmacokinet 57:577–89. doi:10.1007/s40262-017-0576-7.
   PubMed Web of Science ®Google Scholar
• Maliwal, B. P., and F. E. Guthrie. 1983. Chemical modifications of the insecticide binding-sites on human-serum albumin - role of indole, bilirubin, and fatty-acid binding-sites. Pest Biochem. Phys. 19:104–13. doi:10.1016/0048–3575(83)90048–2.
   Web of Science ®Google Scholar
• Mayer, H., R. Burghaus, K. Coböken, S. Frechen, I. Ince, J. Schlender, and A. Bayer. 2018. A novel approach to estimate ontogenies for PBPK applications–from literature data to simulations Population Approach Group Europe (PAGE), 27 Abstr 8583 [www.page-meeting.org/?abstract=8583].
   Google Scholar
• McNamara, P. J., and J. Alcorn. 2002. Protein binding predictions in infants. AAPS PharmSci. 4:E4. doi:10.1208/ps040104.
   PubMedGoogle Scholar
• McNamara, P. J., and D. Meiman. 2019. Predicting drug binding to human serum albumin and alpha one acid glycoprotein in diseased and age patient populations. J. Pharm. Sci. 108:2737–47. doi:10.1016/j.xphs.2019.03.018.
   PubMed Web of Science ®Google Scholar
• Meek, M. E., A. Renwick, E. Ohanian, M. Dourson, B. Lake, B. D. Naumann, and V. Vu, and S. International Programme on Chemical. 2002. Guidelines for application of chemical-specific adjustment factors in dose/ concentration-response assessment. Toxicology 181–182:115–20.
   PubMed Web of Science ®Google Scholar
• Meistelman, C., D. Benhamou, J. Barre, J. C. Levron, V. Mahe, X. Mazoit, and C. Ecoffey. 1990. Effects of age on plasma protein binding of sufentanil. Anesthesiology 72:470–73. doi:10.1097/00000542-199003000-00013.
   PubMed Web of Science ®Google Scholar
• Mohammed, A., A. Eklund, A. M. Ostlundlindqvist, and P. Slanina. 1990. Distribution of toxaphene, DDT, and PCB among lipoprotein fractions in rat and human plasma. Arch. Toxicol. 64:567–71. doi:10.1007/Bf01971836.
   PubMed Web of Science ®Google Scholar
• Notarianni, L. J. 1990. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 18:20–36. doi:10.2165/00003088-199018010-00002.
   PubMed Web of Science ®Google Scholar
• Open Systems Pharmacology. 2018. PK-Sim® ontogeny database version 7.3 http://www.open-systems-pharmacology.org.
   Google Scholar
• Pacifici, G. M., A. Viani, G. Taddeuccibrunelli, G. Rizzo, M. Carrai, and H. U. Schulz. 1986. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma-concentrations of albumin and alpha-1-acid glycoprotein - implications for binding of drugs. Ther. Drug Monit. 8:259–63. doi:10.1097/00007691–198609000–00003.
   PubMed Web of Science ®Google Scholar
• Peters, T., Jr. 1995. All about albumin: Biochemistry, genetics, and medical applications, 256–58. Academic Press, San Diego, CA.
   Google Scholar
• Putnam, F. W. 1975. Alpha, beta, gamma, omega—the roster of the plasma proteins. In The plasma proteins, 57–131. Elsevier, New York, NY.
   Google Scholar
• Sethi, P. K., S. Muralidhara, J. V. Bruckner, and C. A. White. 2014. Measurement of plasma protein and lipoprotein binding of pyrethroids. J. Pharmacol. Toxicol. Meth. 70:106–11. doi:10.1016/j.vascn.2014.06.002.
   PubMed Web of Science ®Google Scholar
• Sethi, P. K., C. A. White, B. S. Cummings, R. N. Hines, S. Muralidhara, and J. V. Bruckner. 2016. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatr. Res. 79:409–15. doi:10.1038/pr.2015.237.
   PubMed Web of Science ®Google Scholar
• Urien, S., P. Riant, E. Albengres, R. Brioude, and J.-P. Tillement. 1984. In vitro studies on the distribution of probucol among human plasma lipoproteins. Mol. Pharmacol. 26:322–27.
   PubMed Web of Science ®Google Scholar
• US EPA. 2014. Guidance for applying quantitative data to develop data-derived extrapolation factors for interspecies and intraspecies extrapolation. Epa/100/r-14/002f. Washington, DC: US EPA.
   Google Scholar
• Valcke, M., and K. Krishnan. 2011. Evaluation of the impact of the exposure route on the human kinetic adjustment factor. Regul. Toxicol. Pharmacol. 59:258–69. doi:10.1016/j.yrtph.2010.10.008.
   PubMed Web of Science ®Google Scholar
• Wallace, S. 1977. Altered plasma albumin in the newborn infant. Br. J. Clin. Pharmacol. 4:82–85.
   PubMed Web of Science ®Google Scholar
• Wasan, K. M., and S. M. Cassidy. 1998. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411–24. doi:10.1021/js970407a.
   PubMed Web of Science ®Google Scholar
• Watanabe, R., T. Esaki, H. Kawashima, Y. Natsume-Kitatani, C. Nagao, R. Ohashi, and K. Mizuguchi. 2018. Predicting fraction unbound in human plasma from chemical structure: Improved accuracy in the low value ranges. Mol. Pharmacol. 15:5302–11. doi:10.1021/acs.molpharmaceut.8b00785.
   PubMed Web of Science ®Google Scholar
• Weaving, G., G. F. Batstone, and R. G. Jones. 2016. Age and sex variation in serum albumin concentration: An observational study. Ann. Clin. Biochem. 53:106–11. doi:10.1177/0004563215593561.
   PubMed Web of Science ®Google Scholar
• Windorfer, A., W. Kuenzer, and R. Urbanek. 1974. The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding. Eur. J. Clin. Pharmacol. 7:227–31.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2010. Characterization and application of physiologically based pharmacokinetic models in risk assessment. World Health Organization, International Programme on Chemical Safety
   Google Scholar
• Yaster, M. 1987. The dose response of fentanyl in neonatal anesthesia. Anesthesiology 66:433–35.
   PubMed Web of Science ®Google Scholar
• Yun, Y. E., and A. N. Edginton. 2019. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. J. Toxicol. Environ. Health Part A 82:789–814.
   PubMed Web of Science ®Google Scholar
• Zhou, W. D., T. N. Johnson, K. H. Bui, S. Y. A. Cheung, J. G. Li, H. M. Xu, N. Al-Huniti, and D. S. Zhou. 2018. Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin. Pharmacol. Ther. 104:188–200. doi:10.1002/cpt.905.
   PubMed Web of Science ®Google Scholar